New drug GB261 tested for rare Hardening-Skin disease
NCT ID NCT07159009
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called GB261 in 10 people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The main goal is to check safety and how the body handles the drug. Researchers will also look for early signs that it might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB261
- What this could lead to
- If it works, this could point toward a new treatment option for systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening.
- What could go wrong
- This is a very early, small trial with only 10 participants. It primarily checks safety, not effectiveness, so the drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.